CA 170

Drug Profile

CA 170

Alternative Names: CA-170

Latest Information Update: 15 Nov 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Discovery Technologies; Curis
  • Class Antineoplastics; Small molecules
  • Mechanism of Action CD274 antigen inhibitors; Programmed cell death 1 ligand 2 protein inhibitors; VISTA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Lymphoma; Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 09 Nov 2016 Early pharmacokinetics and Immunogenicity data from a phase I trial in Solid tumours and Lymphoma (Late-stage disease) released by Curis
  • 01 Jun 2016 Phase-I clinical trials in Lymphoma (Late-stage disease) in USA (PO) (NCT02812875)
  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (PO) (NCT02812875)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top